BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 18264725)

  • 1. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.
    Fan J; Yin WJ; Lu JS; Wang L; Wu J; Wu FY; Di GH; Shen ZZ; Shao ZM
    J Cancer Res Clin Oncol; 2008 Aug; 134(8):883-90. PubMed ID: 18264725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of ER alpha in chemically induced MDA-MB-435 cells and its responsiveness to endocrine].
    Fan J; Lu JS; Yin WJ; Lei W; Wu FY; Wu J; Hou YF; Li DQ; Di GH; Shen ZZ; Shao ZM
    Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):886-9. PubMed ID: 17533736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
    Yang X; Phillips DL; Ferguson AT; Nelson WG; Herman JG; Davidson NE
    Cancer Res; 2001 Oct; 61(19):7025-9. PubMed ID: 11585728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
    Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
    Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
    Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
    Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells.
    Bovenzi V; Momparler RL
    Cancer Chemother Pharmacol; 2001 Jul; 48(1):71-6. PubMed ID: 11488527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines.
    Yan L; Nass SJ; Smith D; Nelson WG; Herman JG; Davidson NE
    Cancer Biol Ther; 2003; 2(5):552-6. PubMed ID: 14614325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.
    Jang ER; Lim SJ; Lee ES; Jeong G; Kim TY; Bang YJ; Lee JS
    Oncogene; 2004 Mar; 23(9):1724-36. PubMed ID: 14676837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.
    Sharma D; Saxena NK; Davidson NE; Vertino PM
    Cancer Res; 2006 Jun; 66(12):6370-8. PubMed ID: 16778215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The synergistic inhibitory effect of 5-aza-2-deoxycytidine and Tamoxifen on estrogen receptor alpha negative breast cancer cell lines in vitro].
    Tang B; Peng ZH; Jiang J
    Zhonghua Wai Ke Za Zhi; 2005 Dec; 43(23):1545-9. PubMed ID: 16412295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trichostatin A and 5 Aza-2' deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR.
    Pryzbylkowski P; Obajimi O; Keen JC
    Breast Cancer Res Treat; 2008 Sep; 111(1):15-25. PubMed ID: 17891453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance.
    Pitta CA; Papageorgis P; Charalambous C; Constantinou AI
    Cancer Lett; 2013 Sep; 337(2):167-76. PubMed ID: 23752064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scriptaid effects on breast cancer cell lines.
    Giacinti L; Giacinti C; Gabellini C; Rizzuto E; Lopez M; Giordano A
    J Cell Physiol; 2012 Oct; 227(10):3426-33. PubMed ID: 22213035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Demethylation of estrogen receptor gene and its re-expression in estrogen receptor-negative breast].
    Wang R; Li LW; Wang RL; Fan QX; Zhao PR; Wang LX; Lu SH
    Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):894-7. PubMed ID: 17533738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells.
    Keen JC; Garrett-Mayer E; Pettit C; Mack KM; Manning J; Herman JG; Davidson NE
    Cancer Biol Ther; 2004 Dec; 3(12):1304-12. PubMed ID: 15662126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.
    Billam M; Sobolewski MD; Davidson NE
    Breast Cancer Res Treat; 2010 Apr; 120(3):581-92. PubMed ID: 19459041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation.
    Zhou Q; Atadja P; Davidson NE
    Cancer Biol Ther; 2007 Jan; 6(1):64-9. PubMed ID: 17172825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer cells are arrested at different phases of the cell cycle following the re-expression of ARHI.
    Zuo X; Qin Y; Zhang X; Ning Q; Shao S; Luo M; Yuan N; Huang S; Zhao X
    Oncol Rep; 2014 May; 31(5):2358-64. PubMed ID: 24676336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing is everything: order of administration of 5-aza 2' deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity.
    Hostetter CL; Licata LA; Keen JC
    Cancer Lett; 2009 Mar; 275(2):178-84. PubMed ID: 19013015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.